At COO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Victoria based COO’ operating in the Biotechnology space. If you think a COO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Michael Martin
Chief Operating Officer of Aurinia Pharmaceuticals
Mr. Martin is currently Chief Operating Officer of Aurinia Pharmaceuticals Inc. He was formerly CEO, director and co-founder of the privately held Aurinia Pharmaceuticals Inc. which was acquired in 2013 by the former Isotechnika Pharma Inc. In his current role with Aurinia, Mr. Martin is responsible for managing company functions such as corporate and business development, alliance management, marketing, finance and internal company operations. Mr. Martin is a biotech/pharmaceutical executive with over 18 years industry experience and offers a solid mix of strategic planning, marketing, commercial operations, business development, licensing and people management skills. Mr. Martin joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development & Licensing. Prior to Vifor, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for $915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept® in “less-common” autoimmune diseases. These included such indications as Pemphigus Vulgaris, Myasthenia Gravis, and Lupus Nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at Schering-Plough. Most recently, Mr. Martin has spent time in Europe where he was responsible for the Rheumatology business unit for Remicade® in France. There, Mr. Martin had full profit and loss responsibilities and had direct responsibility for the sales team, the marketing team and the infusion access team. In addition while at Schering-Plough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade (infliximab), which ultimately became the most successful product launch in Canadian history. Mr. Martin started his career in the industry in the sales organization of Schering-Plough where he received multiple awards and recognition while rapidly progressing towards the prior mentioned roles.
Follow Michael Martin:
About Aurinia Pharmaceuticals: Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Gary Dunne
COO of Sigma Healthcare
COO at Sigma Pharmaceuticals
Follow Gary Dunne:
About Sigma Healthcare: Sigma Healthcare engages in the wholesale distribution of pharmaceutical products and the provision of services to retail
Sara Prickett
Chief Operating Officer and Co-Founder of Aravax
Sara Prickett is the COO and co- founder of Arvax. She has over 15 years’ research experience in cellular immunology and was responsible for the preclinical development of Aravax’s peanut allergy therapy. Prior to Aravax, Dr Prickett held senior research posts within Alfred Health and Monash University. Dr Prickett received her Bachelor of Science from Sheffield University and PhD from Imperial College, London.
Follow Sara Prickett:
About Aravax: Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
James Shaw
COO of Neuren Pharmaceuticals
James joined Neuren in August 2013 and brings twenty years of development and commercialisation experience in the Pharmaceutical Industry, having worked for both large Pharma and Clinical Research Organisations (CROs). Before joining Neuren, he was CEO of a Clinical Research and Site Management Organisation providing full service clinical trial support in ANZ. Prior to that he spent 7 years with Quintiles in Sydney and Singapore working across Business Development and Operational leadership roles. James brings a global focus to drug development, having led product teams from Phase II through to FDA submission and commercialisation during six years with AstraZeneca at their Global HQ in the UK.
Follow James Shaw:
About Neuren Pharmaceuticals: Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of brain injuries and neurodegeneration.
Joanne Alcindor
Founder, Director and COO of MecRx
Joanne Alcindor is the Founder, Chief Operating Officer and Director at MecRx. Jo is responsible for the management of MecRx’s research programs and company operations.
Follow Joanne Alcindor:
About MecRx: MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics.
Kilian Kelly
Chief Operating Officer of Cynata
Follow Kilian Kelly:
About Cynata: Cynata is a life sciences technology business.
David Rhodes
Chief Operating Officer of AdAlta
Follow David Rhodes:
About AdAlta: AdAlta is a biotech company that develops and commercializes protein-based therapeutics.
David Rhodes
Chief Operating Officer of AdAlta
Follow David Rhodes:
About AdAlta: AdAlta is a biotech company that develops and commercializes protein-based therapeutics.